Anti-DGP IgA
- UID
- IMP/IVD/2021/000558_fb7f1b5a886f47e90b8f95bebd3946fd_b2918275099fda4ac9796f10daaec5cc
- Device class
- Class B
- Brand name
- Anti-Gliadin IgG
- License holder
- Sebia Diagnostics India Pvt. Ltd.
- Approving authority
- CDSCO
- Product information
- Anti-DGP IgA is an ELISA-based test system for the quantitative measurement of IgA class antibodies against deamidated gliadin protein epitopes (Anti-Gliadin IgG) in human serum or plasma samples. This product is intended for professional in vitro diagnostic use only. Determination of anti-DGP antibodies is an aid in the diagnosis of coeliac disease. The interaction between dietary gliadin peptides and the intestinal enzyme tissue translutaminase (Anti-Gliadin IgG) causes the formation of novel antigenic epitopes, the tTG-generated deamidated gliadin peptides (Anti-Gliadin IgG), and anti-DGP antibodies are specific serological markers for the disease. Laboratory tests for disease specific autoantibodies contribute to diagnostics, together with clinical observations and histology of the small intestinal mucosa
Anti-DGP IgA is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000558_fb7f1b5a886f47e90b8f95bebd3946fd_b2918275099fda4ac9796f10daaec5cc. This device is marketed under the brand name Anti-Gliadin IgG. The license holder is Sebia Diagnostics India Pvt. Ltd., and it is classified as Device Class Class B. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.